an update on the phase i trial of bms-986393, a novel gprc5d-targeted car-t, in r/r myeloma
Published 1 month ago • 50 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
3:00
phase i trial of mcarh109, a gprc5d-directed car t-cell, for patients with r/r multiple myeloma
-
3:45
update on phase i trial of teclistamab in r/r myeloma
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:01
car-t updates in myeloma
-
2:30
an update on the current status of car-t therapy in multiple myeloma
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:53
sequencing car t-cells and bispecific antibodies in the treatment of multiple myeloma
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
7:14
car-ts in multiple myeloma: their current role and the future
-
3:56
the future of cancer treatment is here: introducing proton therapy
-
13:47
latest news in myeloma: mrd, bites, and car t-cells
-
2:06
an insight into the sequencing of car-t and bispecifics in myeloma
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
0:53
the future of next-generation sequencing assays in myeloma treatment
-
1:39
phase i/ii trial of adct-602 in b-all
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
4:03
novel technologies in multiple myeloma and how these are changing the field
-
3:27
car-t cells in myeloma
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:05
novel car-t constructs being explored in myeloma: t-charge platform